|
- 积分
- 244
- 威望
- 244
- 包包
- 616
|
本帖最后由 细胞海洋 于 2016-1-23 09:51 编辑
8 P( d# B! ?$ {# d7 V, w+ X3 \; Y* U6 ^, h ^" V
目录. s8 G& q$ f% B8 Y2 d
免疫治疗引领肿瘤治疗新模式 ...................................................................................................... 4
# L* Q* L, ?- ~# O! G抗癌领域新突破 .................................................................................................................. 4
/ u( @" ^. U, @$ c: j: g4 }600 亿美元市场空间 ............................................................................................................ 4: `6 D: [( Q0 z. I" O. S0 S
免疫检查点的突破——PD-1 ....................................................................................................... 5
5 J2 Q* i2 u7 a. d/ g3 x3 PPD-1 单抗——肿瘤免疫治疗的明星 .......................................................................................... 5) s6 g" a0 p8 r* m U
PD-1 重磅产品频出 ............................................................................................................. 57 B% n! |" J9 A6 K! h
在研PD-1 单抗全面开花 ....................................................................................................... 6
4 u3 x! y; k# u8 Q' tPD-1 临床试验数据——适应人群广泛，效果显著 .......................................................................... 7" Q" \6 t$ }6 B- e9 i
PD-1 以优秀的临床表现快速斩获非小细胞肺癌适应症 .................................................................... 9
; ^0 D* m, d+ y1 r4 y% pPD-1 联用——免疫鸡尾酒疗法引爆行业增长点 ............................................................................ 9
5 I: k: U; l/ P: m9 S: n+ _5 p% r. W4 _PD-1 市场前景广阔 ........................................................................................................... 105 u" W2 N1 Z8 b+ [- d9 k
免疫治疗热门靶点——PD-L1 ................................................................................................... 19' r$ P! m* q7 g/ k9 u
PD-L1 单抗免疫疗法原理 .................................................................................................... 19" v# x M- o! Y
PD-L1 单抗在研情况 .......................................................................................................... 19% D6 Q5 l+ J; J
PD-L1 联用——多靶点治疗新选择 ......................................................................................... 19+ D3 y5 w# A# a* g' _
PD-L1 未来市场 ............................................................................................................... 207 v6 z3 k4 H$ w* z
免疫治疗另一靶点——CTLA-4 .................................................................................................. 218 F1 |& m- P; D% x
CTLA-4 单抗免疫疗法原理 ................................................................................................... 21
# @" H9 q& u4 a" ^9 uCTLA-4 单抗已上市产品 ..................................................................................................... 21 }+ F7 y# M" k( O7 z' K) {5 u1 ]# ?
CTLA-4 在研产品.............................................................................................................. 225 p9 x8 P# W5 E& V# Z# ^* w6 h
CTLA-4 的未来，联合用药是出路 .......................................................................................... 23' J+ b4 x! t! j
相关公司简介 ........................................................................................................................ 24
8 D4 `) c& U2 ] t2 f+ d' K君实生物 ........................................................................................................................ 243 d6 C! V" M- y0 e4 V
恒瑞医药（确信买入评级） .................................................................................................. 25. P- P# O- b- P: p) g6 h
百时美施贵宝（BMS） ....................................................................................................... 26
4 J( B' `5 M, q$ y- t& [2 N* X默克（Merck） ................................................................................................................ 27
/ X+ \7 E0 u$ L& Z) }/ V; G
4 G9 B: o% [3 _) X' W2 r* I" Q; ?4 L0 V* {5 A
[hide][/hide] |
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
-
总评分: 威望 + 10
包包 + 20
查看全部评分
|
发表于 2016-1-23 09:08
发表于 2016-1-23 19:55
